Index RUT
P/E -
EPS (ttm) -0.67
Insider Own 18.55%
Shs Outstand 45.55M
Perf Week -16.44%
Market Cap 46.73M
Forward P/E -
EPS next Y -0.90
Insider Trans 1.98%
Shs Float 38.60M
Perf Month -57.13%
Income -27.26M
PEG -
EPS next Q -0.23
Inst Own 24.10%
Short Float 9.25%
Perf Quarter -52.60%
Sales 0.00M
P/S -
EPS this Y -34.47%
Inst Trans -30.31%
Short Ratio 3.92
Perf Half Y -42.00%
Book/sh 0.20
P/B 4.99
EPS next Y -1.17%
ROA -91.15%
Short Interest 3.57M
Perf Year -69.38%
Cash/sh 0.31
P/C 3.15
EPS next 5Y -
ROE -207.83%
52W Range 0.92 - 5.85
Perf YTD -52.60%
Dividend Est. -
P/FCF -
EPS past 5Y 18.26%
ROI -141.62%
52W High -83.15%
Beta 1.65
Dividend TTM -
Quick Ratio 1.71
Sales past 5Y 100.00%
Gross Margin -28100.77%
52W Low 7.55%
ATR (14) 0.17
Dividend Ex-Date -
Current Ratio 1.73
EPS Y/Y TTM 19.42%
Oper. Margin -670885.82%
RSI (14) 28.99
Volatility 9.89% 12.73%
Employees 57
Debt/Eq 1.79
Sales Y/Y TTM -99.99%
Profit Margin -719859.94%
Recom 1.00
Target Price 8.25
Option/Short Yes / Yes
LT Debt/Eq 1.14
EPS Q/Q -5.22%
Payout -
Rel Volume 0.86
Prev Close 0.99
Sales Surprise 947.33%
EPS Surprise -3.63%
Sales Q/Q -
Earnings Mar 18 AMC
Avg Volume 911.50K
Price 0.99
SMA20 -36.64%
SMA50 -41.40%
SMA200 -44.80%
Trades
Volume 785,862
Change -0.04%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-01-21 Initiated
Northland Capital
Outperform
$10
Feb-03-20 Downgrade
Oppenheimer
Outperform → Perform
Mar-27-24 11:28AM
09:57AM
(Thomson Reuters StreetEvents)
Mar-19-24 08:50AM
06:41AM
(Thomson Reuters StreetEvents)
Mar-18-24 08:53PM
05:20PM
Loading…
05:20PM
04:05PM
Mar-13-24 07:00AM
Mar-11-24 07:00AM
Mar-05-24 12:59PM
08:00AM
Mar-04-24 06:21PM
06:06PM
Feb-13-24 07:00AM
Jan-26-24 09:22AM
07:00AM
Loading…
Jan-16-24 07:00AM
Dec-15-23 08:17AM
Nov-14-23 10:38AM
Nov-13-23 04:05PM
Nov-06-23 08:00AM
Nov-02-23 07:00AM
Oct-30-23 03:52PM
07:00AM
Oct-09-23 07:00AM
Sep-21-23 08:00AM
Sep-07-23 08:00AM
Aug-24-23 06:47PM
Aug-16-23 06:00AM
Aug-14-23 09:05AM
Aug-11-23 06:08AM
(Thomson Reuters StreetEvents)
04:05PM
Loading…
Aug-10-23 04:05PM
Aug-09-23 08:00AM
Aug-07-23 08:00AM
Aug-03-23 08:00AM
Jun-26-23 08:00AM
Jun-06-23 09:00AM
Jun-01-23 08:00AM
May-12-23 06:04AM
(Thomson Reuters StreetEvents) -15.20%
May-11-23 04:05PM
May-08-23 04:39PM
08:17AM
08:02AM
08:00AM
02:32AM
May-04-23 08:00AM
Apr-24-23 08:00AM
Apr-05-23 07:46PM
Mar-30-23 04:05PM
Mar-23-23 08:00AM
Feb-28-23 04:05PM
Feb-22-23 06:08AM
Feb-15-23 09:51AM
Jan-12-23 12:47PM
08:00AM
Dec-20-22 08:00AM
Dec-13-22 08:00AM
Dec-08-22 08:00AM
Nov-29-22 08:00AM
Nov-23-22 04:05PM
Nov-13-22 07:04AM
Nov-10-22 04:05PM
Nov-03-22 08:00AM
Oct-21-22 08:00AM
Oct-20-22 08:00AM
Oct-05-22 02:50PM
Sep-30-22 08:00AM
Sep-07-22 08:00AM
Sep-06-22 08:00AM
Aug-10-22 04:05PM
Aug-04-22 08:00AM
Jul-27-22 08:00AM
Jul-18-22 08:00AM
Jul-07-22 08:00AM
Jul-06-22 08:00AM
Jun-29-22 08:53AM
Jun-09-22 10:09AM
08:00AM
Jun-07-22 08:00AM
May-15-22 08:06AM
May-12-22 04:05PM
May-05-22 08:00AM
Apr-20-22 08:00AM
Apr-19-22 08:00AM
Apr-03-22 01:46PM
Mar-31-22 01:17PM
Mar-28-22 04:05PM
Mar-21-22 08:00AM
Mar-15-22 08:00AM
Mar-04-22 09:07AM
07:00AM
Feb-13-22 06:29AM
Feb-08-22 08:00AM
Feb-07-22 08:30AM
Dec-10-21 05:46AM
Nov-17-21 12:00PM
Nov-10-21 06:45PM
04:05PM
Nov-08-21 08:00AM
Nov-05-21 03:25PM
Nov-04-21 04:05PM
Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression, and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Grant Stuart M. 10% Owner Mar 28 '24 Buy 0.98 100,000 98,000 5,430,715 Mar 28 03:50 PM Grant Stuart M. 10% Owner Mar 19 '24 Buy 1.23 50,000 61,500 5,330,715 Mar 20 05:44 PM Grant Stuart M. 10% Owner Mar 08 '24 Buy 1.58 10,717 16,911 5,280,715 Mar 11 08:11 AM Rowe Michael M Chief Executive Officer Dec 04 '23 Buy 1.36 4,890 6,650 32,927 Dec 05 04:54 PM Strahlman Ellen R Director Sep 29 '23 Buy 1.68 4,820 8,098 75,113 Oct 02 10:04 AM Rowe Michael M Chief Executive Officer Sep 19 '23 Buy 1.66 1,400 2,324 28,037 Sep 19 05:17 PM Rowe Michael M Chief Executive Officer Sep 15 '23 Buy 1.75 1,137 1,990 26,637 Sep 19 05:17 PM Grant Stuart M. 10% Owner Aug 17 '23 Buy 1.87 30,000 56,100 5,269,998 Aug 17 03:16 PM Grant Stuart M. 10% Owner Aug 16 '23 Buy 1.91 45,000 85,815 5,239,998 Aug 17 03:16 PM GANDOLFO JOHN P Chief Financial Officer May 31 '23 Buy 2.79 2,000 5,580 8,000 May 31 06:31 PM MATHER CHARLES E IV Director May 26 '23 Buy 2.49 3,000 7,470 77,544 May 30 10:13 AM Kern Bren Chief Operating Officer May 26 '23 Buy 2.73 2,500 6,825 2,500 May 31 10:48 AM Grant Stuart M. 10% Owner May 25 '23 Buy 2.65 88,247 233,855 5,194,998 May 26 12:55 PM Strahlman Ellen R Director May 23 '23 Buy 3.10 10,000 30,976 53,052 May 25 04:45 PM Rowe Michael M Chief Executive Officer May 01 '23 Option Exercise 2.72 10,000 27,200 25,500 May 01 08:47 PM Ianchulev Tsontcho Director May 01 '23 Sale 5.50 90,000 495,000 331,211 May 02 07:38 PM Ianchulev Tsontcho Director Apr 27 '23 Sale 5.00 60,000 300,000 421,211 May 01 12:43 PM Ianchulev Tsontcho Director Apr 14 '23 Sale 4.50 40,000 180,000 481,211 Apr 17 09:05 AM Ianchulev Tsontcho Director Apr 11 '23 Sale 4.00 40,000 160,000 521,211 Apr 12 06:39 PM Ianchulev Tsontcho Director Mar 31 '23 Sale 3.50 40,000 140,000 561,211 Apr 03 08:20 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite